Bruker Uk Limited entered into a conditional sale and purchase agreement to acquire Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders for £5 million on December 21, 2023. The total consideration for the Sale will be payable in cash, subject to customary adjustments for working capital, cash, debt and transaction costs. Completion of the Sale is subject to customary closing conditions being satisfied and the granting of probate relating to a deceased Phasefocus Shareholder and is therefore expected to take place in Q1 2024. James Reeve and George Payne of Allenby Capital Limited acted as financial advisor to Braveheart Investment Group plc.

Bruker Uk Limited completed the acquisition of Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders on Marc h 4, 2024. Adrian Dawkes of Pharmaventures Capital Ltd acted as financial advisor to Phasefocus Holdings.